Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic rhTPO during radical radiotherapy for high-risk esophageal cancer
ChiCTR2300078261Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human thrombopoietin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence of thrombocytopenia during radiotherapy. Started Dec 2023; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300078261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078261.